Biotech Series B Investors & VC Firms
900 firms in this list, with a median first check of $550K. 188 of them lead rounds. Generated from verified public data and updated continuously.
Coinvest Capital
VilniusPre-Seed–Growth$55K – $580K
10 people
GO Capital
Saint Jacques de la LandeSeed–Series B$162K – $2.2M
13 people
Synthesis Capital
LondonSeed–Series C
13 people
3xP Global
LisbonSeries A–Series B$1.1M – $10.8M
3 people
Bios Partners
Fort WorthSeed–Growth
15 people
Mérieux Equity Partners
ParisSeed–Late Stage$3.2M – $86M
11 people
Neulogy Ventures
LuxembourgPre-Seed–Growth$216K – $3.2M
5 people
Pureos Bioventures
PfäffikonSeed–Series C
11 people
Droia Ventures
LeuvenPre-Seed–Series B$540K
7 people
Heran Partners
AntwerpSeed–Series B
12 people
Kumpulan Modal Perdana
Petaling JayaSeed–Late Stage$380K – $1.5M
12 people
Braven
New YorkSeed–Series B
17 people
Criteria Bio Ventures
BarcelonaSeed–Late Stage
8 people
Omega Funds
BostonSeed–Late Stage
17 people
Solasta Ventures
BostonSeed–Series C
8 people
APERTURE Venture Partners
BostonSeed–Series C$1M – $5M
4 people
Fine Structures Ventures
CambridgePre-Seed–Late Stage
9 people
Genesys Capital
TorontoSeed–Series B$730K – $3.6M
9 people
PhotonVentures
HilversumPre-Seed–Late Stage$1.1M – $2.7M
8 people
Sound Bioventures
MalmöSeed–Late Stage
9 people
INCE Capital
ShanghaiSeed–Late Stage
8 people
Tech Council Ventures
SummitSeed–Series B$500K – $3M
7 people
SpringTide Ventures
BostonSeed–Series B$500K – $5M
8 people
Elad Gil
San FranciscoSeed–Growth$100K – $10M
1 person
Related lists
Series B Investors & VC Firms (4094)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Series B Investors & VC Firms in United States (1625)Biotech Series A Investors & VC Firms (1596)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)Healthtech Series B Investors & VC Firms (1216)Fintech Series B Investors & VC Firms (1141)
Data sourced from public filings and firms' own websites — see our methodology.











































































